CLIMB BIO INC(CLYM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CLYM CLIMB BIO INC

Trading 02-04 11:31:57 EST

5.44

+0.29

+5.63%

High5.60	Low5.17	Vol335.72K
Open5.18	D1 Closing5.15	Amplitude8.35%
Mkt Cap259.73M	Tradable Cap167.27M	Total Shares47.74M
T/O1.81M	T/O Rate1.09%	Tradable Shares30.75M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CLYM","market":"US","secType":"STK","nameCN":"CLIMB BIO INC","latestPrice":5.44,"timestamp":1770222626186,"preClose":5.15,"halted":0,"volume":335720,"delay":0,"changeRate":0.05631067961165049,"floatShares":30748027,"shares":47744400,"eps":-0.75067,"marketStatus":"Trading","change":0.29,"latestTime":"02-04 11:31:57 EST","open":5.18,"high":5.6,"low":5.17,"amount":1811136.71662,"amplitude":0.083495,"askPrice":5.46,"askSize":100,"bidPrice":5.42,"bidSize":229,"shortable":3,"etf":0,"ttmEps":-0.75067,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770238800000},"marketStatusCode":2,"adr":0,"listingDate":1628222400000,"exchange":"NASDAQ","adjPreClose":5.15,"preHourTrading":{"tag":"盘前","latestPrice":5.2345,"preClose":5.15,"latestTime":"08:47 EST","volume":46,"amount":240.9420062,"timestamp":1770212856747,"change":0.0845,"changeRate":0.016408,"amplitude":0.00301},"postHourTrading":{"tag":"盘后","latestPrice":5.25,"preClose":5.15,"latestTime":"19:14 EST","volume":6270,"amount":32414.204,"timestamp":1770164094036,"change":0.1,"changeRate":0.019417,"amplitude":0.038835},"volumeRatio":2.535159,"impliedVol":3.6396,"impliedVolPercentile":0.9},"requestUrl":"/m/hq/s/CLYM/wiki","defaultTab":"wiki","newsList":[{"id":"2605849457","title":"Ten new option listings and two option delistings on January 22nd","url":"https://stock-news.laohu8.com/highlight/detail?id=2605849457","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605849457?lang=en_us&edition=fundamental","pubTime":"2026-01-22 21:36","pubTimestamp":1769088965,"startTime":"0","endTime":"0","summary":"New option listings for January 22nd include Aardvark Therapeutics Inc (AARD), Anteris Technologies Global Corp (AVR), Climb Bio Inc (CLYM), REX Dr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ten-new-option-listings-and-two-option-delistings-on-january-22nd-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ten-new-option-listings-and-two-option-delistings-on-january-22nd-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVR","AARD","BK4539","CLYM","BK4139","BK4082"],"gpt_icon":0},{"id":"2602390675","title":"Analysts Offer Insights on Healthcare Companies: Climb Bio (CLYM) and Halozyme (HALO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2602390675","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602390675?lang=en_us&edition=fundamental","pubTime":"2026-01-09 04:01","pubTimestamp":1767902477,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Climb Bio (CLYM – Research Report) and Halozyme (HALO – Research ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-climb-bio-clym-and-halozyme-halo-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-climb-bio-clym-and-halozyme-halo-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLYM","LU0029874061.USD","XBI","BK4539","BK4139","LU0053671581.USD","HALO","XLV","LABU","BK4581","LU0128526141.USD","BK4137","BK4588","HCSG","BK4585"],"gpt_icon":0},{"id":"2601036935","title":"Climb Bio Inc. Outlines 2026 Strategy With Multiple Clinical Trial Readouts, Expanded Pipeline in Immune-Mediated Diseases, and Financial Guidance Extending Operations Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2601036935","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601036935?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:08","pubTimestamp":1767874109,"startTime":"0","endTime":"0","summary":"Climb Bio Inc. Outlines 2026 Strategy With Multiple Clinical Trial Readouts, Expanded Pipeline in Immune-Mediated Diseases, and Financial Guidance Extending Operations Into 2028. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL8s7bC9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","BK4139","BK4539"],"gpt_icon":0},{"id":"2601366299","title":"Climb Bio Inc. Expands Leadership Team and Board with Key Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2601366299","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601366299?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:02","pubTimestamp":1767873730,"startTime":"0","endTime":"0","summary":"Climb Bio Inc. has expanded its senior leadership team with the appointments of Edgar D. Charles, M.D., MSc as Chief Medical Officer, Perrin Wilson, Ph.D., as Chief Business Officer, Susan Altschuller, Ph.D., MBA as Chief Financial Officer, Adam Villa, MS, MBA as SVP, Technical Operations, and Ashley Jones as SVP, People & Workforce Strategy. The company also strengthened its Board of Directors with the addition of Kim Cobleigh Drapkin, CPA and Bo Cumbo.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on January 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL81J7rX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU0314104364.USD","SG9999014021.USD","IE00BKPKM429.USD","SG9999014005.SGD","BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","LU2095319765.USD","CLYM","BK4585","LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014013.SGD","NDAQ","BK4139","BK4539","BK4588","SG9999014039.USD"],"gpt_icon":0},{"id":"2601366419","title":"Climb Bio Reports Progress in Clinical Trials for Budoprutug and CLYM116","url":"https://stock-news.laohu8.com/highlight/detail?id=2601366419","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601366419?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873647,"startTime":"0","endTime":"0","summary":"Climb Bio Inc. announced significant progress in its clinical development programs, with initial data from key trials expected in the second half of 2026. The company has dosed the first patients in the PrisMN Phase 2 trial of budoprutug, its anti-CD19 monoclonal antibody, for primary membranous nephropathy , and is continuing dosing in Phase 1b/2a trials for immune thrombocytopenia  and Phase 1b in systemic lupus erythematosus . Regulatory clearance was achieved for a SLE trial in China, with the first patient dosing anticipated in the first half of 2026. Additionally, the first subjects have been dosed in the Phase 1 healthy volunteer study of CLYM116, Climb Bio's anti-APRIL monoclonal antibody. Initial research results from these studies have not yet been presented but are expected to be reported in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gene","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL9qc6WN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0314104364.USD","SG9999014013.SGD","BK4539","CLYM","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BKPKM429.USD","SG9999014021.USD","IE00B3QW5Z07.USD","BK4112","BK4139","SG9999014039.USD","LU2210149790.SGD","BK4588","NDAQ","IE00BGHQF748.EUR","LU2095319765.USD"],"gpt_icon":0},{"id":"2601366226","title":"Climb Bio Inc: First Patients Dosed in Budoprutug Prismn Phase 2 Trial in Pmn, With Initial Data Expected Second Half 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601366226","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601366226?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873604,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA7SZC2H:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","CLYM"],"gpt_icon":0},{"id":"2601366166","title":"Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601366166","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601366166?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873604,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA7SZC2H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","CLYM"],"gpt_icon":0},{"id":"2601142366","title":"Climb Bio Inc - Cash Runway Expected Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2601142366","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601142366?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA7SZC2H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLYM","BK4539","BK4139"],"gpt_icon":0},{"id":"2601738144","title":"RA Capital Management Reports Acquisition of Climb Bio Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2601738144","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601738144?lang=en_us&edition=fundamental","pubTime":"2026-01-08 05:56","pubTimestamp":1767822990,"startTime":"0","endTime":"0","summary":"RA Capital Management, L.P. reported the acquisition of common shares of Climb Bio Inc. , according to a recent SEC filing. Other reporting beneficial owners include RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., and RA Capital Nexus Fund II, L.P., among other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 07, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL5nMF0y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"RA Capital Management Reports Acquisition of Climb Bio Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLYM","BK4539"],"gpt_icon":0},{"id":"2600731704","title":"BRIEF-Climb Bio Files Complaint Against Alumis And Acelyrin - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2600731704","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600731704?lang=en_us&edition=fundamental","pubTime":"2026-01-01 06:36","pubTimestamp":1767220603,"startTime":"0","endTime":"0","summary":"BRIEF-Climb Bio Files Complaint Against Alumis And Acelyrin - SEC FilingDec 31  - Climb Bio Inc CLYM.O:CLIMB BIO INC - FILES COMPLAINT AGAINST ALUMIS AND ACELYRIN - SEC FILINGCLIMB BIO INC - COMPLAINT RELATING TO A DISPUTE CONCERNING AN ASSET PURCHASE AGREEMENT, DATED AS OF JANUARY 11, 2024CLIMB BIO INC - COMPLAINT SEEKS DECLARATORY JUDGMENT THAT CO'S BUDOPRUTUG DRUG CANDIDATE IS NOT \"PRODUCT\" UNDER APACLIMB BIO INC - DOES NOT OWE A MILESTONE PAYMENT SOUGHT BY ALUMIS IN CONNECTION WITH ITS DEVELOPMENT OF BUDOPRUTUGSource text: [ID:n0001193125-25-338318]Further company coverage: CLYM.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nFWN3Y106H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLYM","BK4539"],"gpt_icon":0},{"id":"2600701810","title":"Climb Bio Inc - Files Complaint Against Alumis and ACELYRIN - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2600701810","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600701810?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:14","pubTimestamp":1767215642,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nFWN3Y106H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","CLYM","BK4139"],"gpt_icon":0},{"id":"2600701355","title":"Climb Bio Inc - Complaint Seeks Declaratory Judgment That Co's Budoprutug Drug Candidate Is Not \"Product\" Under Apa","url":"https://stock-news.laohu8.com/highlight/detail?id=2600701355","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600701355?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:14","pubTimestamp":1767215642,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nFWN3Y106H:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","CLYM"],"gpt_icon":0},{"id":"2600570133","title":"Climb Bio Inc - Does Not Owe a Milestone Payment Sought by Alumis in Connection With Its Development of Budoprutug","url":"https://stock-news.laohu8.com/highlight/detail?id=2600570133","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600570133?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:14","pubTimestamp":1767215642,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nFWN3Y106H:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLYM","BK4539"],"gpt_icon":0},{"id":"2600018177","title":"Climb Bio Inc - Complaint Relating to a Dispute Concerning an Asset Purchase Agreement, Dated as of January 11, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2600018177","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600018177?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:14","pubTimestamp":1767215642,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nFWN3Y106H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","CLYM"],"gpt_icon":0},{"id":"2600701814","title":"Climb Bio Sues Alumis Over $3 Million Milestone Dispute","url":"https://stock-news.laohu8.com/highlight/detail?id=2600701814","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600701814?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:13","pubTimestamp":1767215610,"startTime":"0","endTime":"0","summary":"Climb Bio Inc., a Massachusetts-based biotechnology company, has filed a lawsuit seeking resolution of a dispute with Alumis Inc. and its subsidiary Acelyrin Inc. The litigation centers on a January 2024 Asset Purchase Agreement, under which Climb acquired assets related to the drug candidate budoprutug. Climb alleges that despite not receiving any royalty-bearing patents from Alumis or Acelyrin, it was invoiced for a $3 million milestone payment after dosing its first patient in a Phase 2 clinical trial. Climb maintains that its payment obligations are limited to products that would infringe patents included in the transferred assets or filed within nine months of the agreement’s closing, which it claims it did not receive. The company is seeking the court’s intervention to clarify its obligations and resolve the ongoing dispute.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDL9hWHb3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","BK4007","BK4139","ALMS","BK4539"],"gpt_icon":0},{"id":"2595275302","title":"Retail investors in Climb Bio, Inc. (NASDAQ:CLYM) are its biggest bettors, and their bets paid off as stock gained 15% last week","url":"https://stock-news.laohu8.com/highlight/detail?id=2595275302","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595275302?lang=en_us&edition=fundamental","pubTime":"2025-12-28 20:25","pubTimestamp":1766924736,"startTime":"0","endTime":"0","summary":"Key Insights Significant control over Climb Bio by retail investors implies that the general public has more power to...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-clym/climb-bio/news/retail-investors-in-climb-bio-inc-nasdaqclym-are-its-biggest","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-clym/climb-bio/news/retail-investors-in-climb-bio-inc-nasdaqclym-are-its-biggest","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","QID","TSYW.SI","QLD",".IXIC","TQQQ","SQQQ","NQmain","NVIW.SI","BK4539","USAW.SI","CLYM","USJW.SI","PSQ","MNQmain"],"gpt_icon":1},{"id":"2592290381","title":"Climb Bio Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2592290381","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592290381?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:09","pubTimestamp":1766059740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLYM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 18, 2025 07:09 ET (12:09 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","CLYM","BK4139"],"gpt_icon":0},{"id":"2592927648","title":"U.S. RESEARCH ROUNDUP-Autozone, Coursera, Lennar","url":"https://stock-news.laohu8.com/highlight/detail?id=2592927648","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592927648?lang=en_us&edition=fundamental","pubTime":"2025-12-18 14:42","pubTimestamp":1766040152,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Autozone, Coursera, LennarDec 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Autozone, Courser","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nL4N3XO0FW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASH","ALSN","CLW","BK4090","BBNX","DAL","BK4107","BRO","AXTA","LU0345769631.USD","CTVA","CE","HOUS","ARDT","ALL","BTSG","IE00B7SZLL34.SGD","DOW","DD","BIIB","CLYM","SGXZ57979304.SGD","COUR","AJG","BAC","BK4147","ACHC","BK4548","CGNX","ALB","AVTX","BCAX","AAL","ACM","SG9999001176.USD","DG","CBT","LU0234570918.USD","AMAT","CMI","BSX","LU1989763690.USD","AMRZ","CL","CRL","AZO","ACAD","CF","CPT","APD"],"gpt_icon":0},{"id":"2590516121","title":"Climb Bio Inc - Enters Exchange Agreement With Ra Capital - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2590516121","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590516121?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:17","pubTimestamp":1765459037,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nFWN3XH0QG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","CLYM"],"gpt_icon":0},{"id":"2590516142","title":"Climb Bio Announces Exchange of 20.4 Million Shares for Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2590516142","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590516142?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:16","pubTimestamp":1765459005,"startTime":"0","endTime":"0","summary":"Climb Bio Inc. has announced it entered into an exchange agreement with RA Capital Management, L.P. and an affiliated entity, under which 20,440,000 shares of the company's common stock held by the investor will be exchanged for a pre-funded warrant to purchase an equal number of shares at an exercise price of $0.0001 per share. The pre-funded warrant is exercisable at any time after issuance. The shares underlying the warrant are being issued without registration under the Securities Act of 1933, relying on the exemption provided by Section 3. Upon completion of the transaction and retirement of the exchanged shares, Climb Bio will have 47,744,435 shares of common stock outstanding, with RA Capital and its affiliates owning approximately 23% of the company's voting power.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDLX0Fql:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","CLYM","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eliemtx.com","stockEarnings":[{"period":"1week","weight":0.0059},{"period":"1month","weight":0.3733},{"period":"3month","weight":1.6823},{"period":"6month","weight":2.0655},{"period":"1year","weight":1.5879},{"period":"ytd","weight":0.2875}],"compareEarnings":[{"period":"1week","weight":-0.0086},{"period":"1month","weight":0.0093},{"period":"3month","weight":0.0176},{"period":"6month","weight":0.0906},{"period":"1year","weight":0.1535},{"period":"ytd","weight":0.0112}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.012175},{"month":2,"riseRate":0.6,"avgChangeRate":-0.000897},{"month":3,"riseRate":0.25,"avgChangeRate":-0.102291},{"month":4,"riseRate":0.75,"avgChangeRate":0.286337},{"month":5,"riseRate":0.5,"avgChangeRate":0.027501},{"month":6,"riseRate":0.25,"avgChangeRate":-0.069889},{"month":7,"riseRate":0.75,"avgChangeRate":0.07628},{"month":8,"riseRate":0.25,"avgChangeRate":0.096778},{"month":9,"riseRate":0.2,"avgChangeRate":-0.124516},{"month":10,"riseRate":0.4,"avgChangeRate":-0.049478},{"month":11,"riseRate":0,"avgChangeRate":-0.130257},{"month":12,"riseRate":0.6,"avgChangeRate":0.177771}],"exchange":"NASDAQ","name":"CLIMB BIO INC","nameEN":"CLIMB BIO INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CLIMB BIO INC(CLYM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CLIMB BIO INC(CLYM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CLIMB BIO INC,CLYM,CLIMB BIO INC股票,CLIMB BIO INC股票老虎,CLIMB BIO INC股票老虎国际,CLIMB BIO INC行情,CLIMB BIO INC股票行情,CLIMB BIO INC股价,CLIMB BIO INC股市,CLIMB BIO INC股票价格,CLIMB BIO INC股票交易,CLIMB BIO INC股票购买,CLIMB BIO INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CLIMB BIO INC(CLYM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CLIMB BIO INC(CLYM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}